Published in J Med Genet on June 18, 2009
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat (2011) 1.33
BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol (2010) 1.32
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer (2012) 1.24
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet (2011) 1.23
BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer (2013) 1.19
Risk determination and prevention of breast cancer. Breast Cancer Res (2014) 1.11
BRCA1/2 mutations and triple negative breast cancers. Breast Dis (2010) 0.99
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res (2014) 0.99
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. Breast Cancer Res (2012) 0.96
BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet (2015) 0.94
Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer (2010) 0.92
The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers. Fam Cancer (2010) 0.90
Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. Int J Surg Oncol (2011) 0.86
Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch (2010) 0.86
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet (2012) 0.84
Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. Eur J Hum Genet (2014) 0.80
The biological effects and clinical implications of BRCA mutations: where do we go from here? Eur J Hum Genet (2016) 0.78
Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing. Eur J Hum Genet (2016) 0.76
Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. Fam Cancer (2016) 0.75
Novel Aryl Hydrocarbon Receptor Agonist Suppresses Migration and Invasion of Breast Cancer Cells. PLoS One (2016) 0.75
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Performance of skin biopsies by general practitioners. BMJ (1991) 4.51
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
An in vitro method for assessing the plaque forming ability of oral bacteria. Arch Oral Biol (1967) 3.11
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer (1984) 2.89
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest (1972) 2.88
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med (1986) 2.85
Itch: scratching more than the surface. QJM (2003) 2.75
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68
Familial breast cancer. BMJ (1994) 2.54
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
Uptake of screening and prevention in women at very high risk of breast cancer. Lancet (2001) 2.45
Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls. Radiographics (2000) 2.40
The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin. Tissue Antigens (1978) 2.40
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol (1997) 2.39
Perception of risk in women with a family history of breast cancer. Br J Cancer (1993) 2.32
The beta2-microglobulin gene is on chromosome 15 and not in the HL-A region. Nature (1975) 2.29
The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology (1995) 2.27
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet (2003) 2.24
Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol (1998) 2.18
Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J Virol (1994) 2.17
Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A (2010) 2.05
Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet (2009) 2.05
Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med (1981) 1.96
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet (2008) 1.90
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat (2001) 1.88
Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia (2008) 1.87
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat (1999) 1.84
Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer (1991) 1.83
Systematic review: hepatitis-associated aplastic anaemia--a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther (2009) 1.83
The role of cell-surface receptors in the transport and catabolism of immunoglobulins. Ciba Found Symp (1972) 1.80
Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer (2007) 1.80
Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab (1997) 1.79
The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer (1994) 1.75
Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology (1988) 1.74
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 1.70
Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet (1983) 1.69
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer (1996) 1.67
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
Histopathology and prognosis of malignant colorectal polyps treated by endoscopic polypectomy. Gut (1984) 1.66
The Budd-Chiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology (1975) 1.66
The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer (1989) 1.65
Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer (2001) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) (2010) 1.61
Odontomyces viscosus, gen. nov., spec. nov., a filamentous microorganism isolated from periodontal plaque in hamsters. Sabouraudia (1965) 1.61
The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer (1984) 1.61
Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med (1991) 1.59
Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J Natl Cancer Inst (1997) 1.58
Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol (2007) 1.57
Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet (1984) 1.56
The chronic sequelae of non-A, non-B hepatitis. Ann Intern Med (1979) 1.54
Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia (1998) 1.52
A filamentous microorganism isolated from periodontal plaque in hamsters. 1. Isolation, morphology and general cultural characteristics. Sabouraudia (1963) 1.52
Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J Clin Invest (1983) 1.52
The UK Northern region genetic register for familial adenomatous polyposis coli: use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations. J Med Genet (1991) 1.51
Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol (1996) 1.49
Can hair be used to screen for breast cancer? J Med Genet (2000) 1.49
Can preoperative factors predict for residual malignancy after breast biopsy for invasive cancer? Ann R Coll Surg Engl (1995) 1.47
A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther (2000) 1.45
Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest (1978) 1.45
Neuropathic joints. Semin Arthritis Rheum (1972) 1.44
Screening by mammography, women with a family history of breast cancer. Eur J Cancer (1998) 1.44
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol (1996) 1.44
Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol (1999) 1.43
Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol (1998) 1.43
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations. Clin Endocrinol (Oxf) (1994) 1.42
Genetics and serology of HL-A-linked human Ia antigens. Cold Spring Harb Symp Quant Biol (1977) 1.42
Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab (1999) 1.42
The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. Br J Cancer (1988) 1.42
Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Colorectal Dis (2015) 1.40
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer (2012) 1.39
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole. Eur J Cancer (2004) 1.39
Effect of clothing on dispersal of Staphylococcus aureus by males and females. Lancet (1974) 1.39
The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A (1989) 1.38
Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer (1993) 1.36
Abnormal regulation of immunoglobulin synthesis in vitro in primary biliary cirrhosis. Gastroenterology (1980) 1.36
NIH conference: Primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med (1983) 1.35
Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet (1983) 1.35
A filamentous microorganism isolated from periodontal plaque in hamsters. II. Physiological and biochemical characteristics. Sabouraudia (1963) 1.34
Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med (1987) 1.33
Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psychooncology (1999) 1.32